经口机器人手术治疗声门上型鳞状细胞癌的肿瘤学结局:法国GETTEC机器人手术组结果
平均随访42.8个月,2年局部控制率94.3%,5年90.2%;2年总生存率和无病生存率分别为86.9%和95.1%,5年分别为78.7%和94.3%。51.6%患者接受辅助放疗,其中16例因切缘近或阳性。结论认为经口机器人手术的局部控制率至少等同于文献中开放手术、经口激光手术或放疗,对早中期声门上型鳞状细胞癌有效。
要点
- 经口机器人声门上喉切除术2年局部控制率94.3%,5年90.2%。
- 2年总生存率86.9%、无病生存率95.1%;5年分别为78.7%、94.3%。
- 51.6%患者接受辅助放疗,16例因切缘近或阳性。
核心结论
- 经口机器人声门上喉切除术的局部控制率至少等同于文献中开放手术、经口激光手术或放疗。
- 经口机器人手术似乎是治疗早中期声门上型鳞状细胞癌的有效方式。
研究设计与样本
- 多中心观察性研究,纳入接受经口机器人手术行声门上喉切除术的声门上型鳞状细胞癌患者,随访至少2年。
主要发现
- 2年局部控制率94.3%,5年局部控制率90.2%。
- 2年总生存率86.9%,5年总生存率78.7%。
- 2年无病生存率95.1%,5年无病生存率94.3%。
临床怎么用
- 经口机器人手术可作为早中期声门上型鳞状细胞癌的治疗选择。
- 术后需根据切缘状态等决定是否辅助放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transoral robotic surgery (TORS) is an option to treat supraglottic squamous cell carcinomas (SCCs). We studied the oncologic outcomes after TORS for supraglottic laryngectomy (SGL). METHODS: We conducted a multicenter observational study of SGL using TORS for patients with supraglottic SCC with at least 2 years of follow-up. RESULTS: One hundred twenty-two patients were included in our study. Mean follow-up was 42.8 months. Local control was 94.3% at 2 years and 90.2% at 5 years. Overall survival and disease-free survival were 86.9% and 95.1% at 2 years, and 78.7% and 94.3% at 5 years, respectively. Sixty-three patients (51.6%) received adjuvant radiotherapy. For 16 of them, this was due to close or positive margins. CONCLUSION: Local control rate after TORS SGL was at least equivalent to what has been described in the literature for open or transoral laser surgery, or with radiotherapy. Using TORS seems to be an effective therapeutic treatment of early-stage and intermediate-stage supraglottic SCCs.
引用
- Doazan M, Hans S, Morinière S, et al. Oncologic outcomes with transoral robotic surgery for supraglottic squamous cell carcinoma: Results of the French Robotic Surgery Group of GETTEC. Head Neck. 2018. PMID: 30051531. doi:10.1002/hed.25199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。